Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics

Clinical Pediatrics

Volumn 49, Issue 5, 2010, Pages 485-490

  Halloran, Donna R ^a   Swindle, Jason ^a   Takemoto, Steve K ^a   Schnitzler, Mark A ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Antipsychotic agents; Insurance; Mental disorders; Prevalence

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; DEVELOPMENTAL DISORDER; DISRUPTIVE BEHAVIOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; PRIVATE HEALTH INSURANCE; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE, PSYCHIATRIC; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MENTAL DISORDERS; MOOD DISORDERS; ODDS RATIO; PREVALENCE; PRIVATE SECTOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; TREATMENT OUTCOME; UNITED STATES;

EID: 77952968254     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922809347369     Document Type: Article

References (51)

1. Cooper WO, Arbogast PG, Ding H., et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006; 6: 79-83.
2. Patel NC, Crismon ML, Hoagwood K., et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005; 44: 548-556. (Pubitemid 40720954)
3. Correll CU Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008; 47: 9-20.
4. Patel NC, Hariprasad M., Matias-Akthar M., et al. Body mass index and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol. 2007; 17: 303-311.
5. Wonodi I., Reeves G., Carmichael D., et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord. 2007; 22: 1777-1782.
6. McNicholas F., Motala F. Transient ischemic attach with risperidone and clonidine. J Am Acad Child Adolesc Psychiatry. 2007; 46: 1530-1531.
7. Wieck A., Haddad PM Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry. 2003; 182: 199-204.
8. Findling RL, Steiner H., Weller EB Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005; 66: 29-40.
9. Patel NC, Kistler JS, James EB, et al. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy. 2004; 24: 825-830.
10. Correl CU, Carlson HE Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006; 45: 771-791.
11. Harrison-Woolrych M., Garcia-Quiroga J., Ashton J., Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf. 2007; 30: 569-579.
12. McIntyre RS, Jerrell JM Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. 2008; 162: 929-935.
13. Sikich L., Frazier JA, McClellan J., et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008; 165: 1420-1431.
14. Sanford M., Keating GM Aripiprazole: in adolescents with schizophrenia. Paediatr Drugs. 2007; 9: 419-423.
15. Luby JL, Stalets M., Belden A. Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods. J Child Adolesc Psychopharmacol. 2007; 17: 205-215.
16. Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006; 21: 450-455.
17. Tohen M., Kryzhanovskaya L., Carlson G., et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007; 164: 1547-1556.
18. McClellan JM Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns. Am J Psychiatry. 2007; 164: 1462-1464.
19. Sporn AL, Vermani A., Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007; 46: 1349-1356.
20. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007; 17: 334-347.
21. Snyder R., Turgay A., Aman M., et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002; 41: 1026-1036.
22. Findling RL, Reed MD, Og'Riordan MA, et al. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007; 17: 1-9.
23. Strawn JR, Delbello MP Olanzapine for the treatment of bipolar disorder in children and adolescents. Expert Opin Pharmacother. 2008; 9: 467-474.
24. US Department of Health and Human Services. FDA approves risperdal for two psychiatric conditions in children and adolescents. FDA News. August 22, 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108969. htm. Accessed July 27, 2009.
25. US Department of Health and Human Services. FDA approves the first drug to treat irritability associated with autism, risperdal. FDA News. October 6, 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759. htm. Accessed July 27, 2009.
26. Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother. 2006; 40: 205-211.
27. Curtis LH, Masselink LE, stbye T., et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med. 2005; 159: 362-366.
28. Rani F., Murray ML, Byrne PJ, Wong ICK. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008; 121: 1002-1009.
29. Martin A., Sherwin T., Stubbe D., et al. Use of multiple psychotropic drugs by Medicaid-insured and privately insured children. Psychiatr Serv. 2002; 53: 1508.
30. Sturm R., Ringel JS, Andreyeva T. Geographic disparities in childreng's mental health care. Pediatrics. 2003; 112: e308-e315.
31. Hermann RC, Yang D., Ettner SL, et al. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002; 53: 425-430.
32. Cooper WO, Hickson GB, Fuchs C., et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004; 158: 753-759.
33. Olfson M., Blanco C., Liu L., et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006; 63: 679-685.
34. Guevara J., Lozano P., Wickizer T., Mell L., Gephart H. Psychotropic medication use in a population of children who have attention-deficit/ hyperactivity disorder. Pediatrics. 2002; 109: 733-739.
35. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J., Polsky DE Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008; 121: e441-e448.
36. dosReis S., Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol. 2005; 15: 68-77.
37. Zito JM, Safer DJ, Devadatta S., et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008; 121: e157-e163.
38. Rappley MD, Eneli IU, Mullan PB, et al. Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002; 23: 23-29.
39. Bussing R., Levin GM Methamphetamine and fluoxetine treatment of a child with attention deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 1993; 3: 53-58.
40. Gammon GD, Brown TE Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and co-morbid depressive disorder. J Child Adolesc Psychopharmacol. 1991; 3: 1-10.
41. Parraga HC, Kelly DP, Parraga MI, Cochran MK, Maxim LT Combined psychostimulant and tricyclic antidepressant treatment of Touretteg's syndrome and comorbid disorders in children. J Child Adolesc Psychopharmacol. 1994; 4: 113-122.
42. Findling RL Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin re-uptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 1996; 6: 165-175.
43. Hawkridge S., Stein DJ, Bouwer C. Combined pharmacotherapy for TS and OCD (letter). J Am Acad Child Adolesc Psychiatry. 1996; 35: 703-704.
44. Safer DJ, Zito JM, Dosreis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003; 160: 438-439.
45. Gerardin P., Cohen D., Mazet P., et al. Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol. 2002; 12: 361-370.
46. Glick ID, Murray SR, Vasudevan P., et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001; 35: 187-191.
47. Cheng-Shannon J., McGough JJ, Pataki C., et al. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004; 14: 372-394.
48. McCracken JT, McGough J., Shah B., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2007; 347: 314-321.
49. Shekelle P., Maglione M., Bagley S., et al. Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Comparative effectiveness review No. 6. http://effectivehealthcare.ahrq.gov/repFiles/ Atypical-Antipsychotics-Final-Report.pdf. Published January 2007. Accessed July 27, 2009.
50. Aman MG, De Smedt G., Derivan A., et al. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002; 159: 1337-1346.
51. Croonenberghs J. Risperidone in children with disruptive behavior disorders: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2005; 44: 64-72.